<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033158</url>
  </required_header>
  <id_info>
    <org_study_id>001752</org_study_id>
    <nct_id>NCT05033158</nct_id>
  </id_info>
  <brief_title>The Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population.</brief_title>
  <acronym>REAL-V</acronym>
  <official_title>Investigation to Reveal the Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population: COVID-19 Protection and Vaccine Safety (REAL-V)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KomOpTegenKanker (non-profit organization)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the immune response in the cancer population in Belgium being&#xD;
      vaccinated with an approved vaccine types being authorized for use in Belgium. This question&#xD;
      needs to be answered to make sure that this vulnerable population is properly protected&#xD;
      against possible SARS-CoV-2 infection and that vaccine administration is safe.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Patients with cancer have an increased risk of adverse outcome of COVID-19 and&#xD;
      should be at high prioritisation for vaccination against SARS-CoV-2. The COVID-19 vaccine&#xD;
      trials have not included cancer patients as such, the efficacy and duration of immunity in&#xD;
      patients with cancer are still unknown. Keeping in mind that cancer patients are often&#xD;
      immunocompromised, the immune response upon vaccination needs further investigation.&#xD;
&#xD;
      The REAL-V is a prospective, multicenter cohort study. The humoral immunity response based on&#xD;
      anti-SARS-CoV-2 IgG antibodies upon COVID-19 vaccination will be investigated in blood&#xD;
      samples taken 4 months, 6 months and 12 months after (first) vaccine administration.&#xD;
      Potential factors that affect immunity, will be recorded, such as type and stage of cancer,&#xD;
      anti-cancer treatment, concomitant medication,..To investigate the safety of different&#xD;
      COVID-19 vaccines, incidence and severity of systemic adverse events will be reported using&#xD;
      an App based system answering questionnaires about specific vaccine related complaints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>4 months</time_frame>
    <description>The primary endpoint is the quantification of different anti-SARS-CoV-2 specific IgG antibodies 4 months after (first) vaccine administration. Antibody titers to the full Spike, S1, S2, RBD (receptor binding domain) and N (nucleocapsid) protein of SARS-CoV-2 will be measured quantitatively. For this measurement a multiplex SARS-CoV-2 immunoassay will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the immune response</measure>
    <time_frame>6 months</time_frame>
    <description>To study the evolution and duration of the immune response after vaccination: using serological assays to analyze anti-RBD IgG titers 6 months after (first) vaccine administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing capacity</measure>
    <time_frame>6 months</time_frame>
    <description>To analyze the titer of neutralizing antibodies both 4 and 6 months after (first) vaccine administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the immune response</measure>
    <time_frame>12 months</time_frame>
    <description>This will be assessed by the SARS-Cov2 infection rate based on information collected through questionnaires on incidence of (PCR-confirmed) SARSCoV-2 infection within a time-frame of 12 months after the start of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine safety</measure>
    <time_frame>12 months</time_frame>
    <description>Safety will be reported in terms of incidence and severity of systemic adverse events (AEs) during a continuous App based reporting system or using a questionnaire 3 days after vaccine administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Level of antibodies against SARS-CoV-2 will be measured in these patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling before and after COVID-19 vaccination</description>
    <arm_group_label>Cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18 years or older&#xD;
&#xD;
          -  Oncological or hematological malignancy or history of it&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Immune deficiency not related to cancer or cancer treatment&#xD;
&#xD;
          -  Allergy (multiple); to be determined by physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Peeters, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Peeters, Prof. MD</last_name>
    <phone>003238213466</phone>
    <email>Marc.Peeters@uza.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter van Dam, Prof. MD</last_name>
    <email>Peter.vanDam@uza.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Peeters, Prof. MD</last_name>
      <email>Marc.Peeters@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wim Demey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint Jan</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Bols</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann De Becker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint Lucas</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Van Ongeval</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Rottey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Hanssens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willem Lybaert</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

